Lyra Therapeutics, Inc.LYRANASDAQ
Loading
SG&A Expense Growth Under PressureDecelerating
Percentile Rank8
Year-over-Year Change
Year-over-year SG&A expense growth
Percentile
P8
Near historical low
vs 5Y Ago
-4.6x
Contraction
Streak
1 qtr
Consecutive declineDecelerating
| Period | Value |
|---|---|
| Q3 2025 | -38.99% |
| Q2 2025 | 7.29% |
| Q1 2025 | -9.69% |
| Q4 2024 | -8.09% |
| Q3 2024 | -23.51% |
| Q2 2024 | -11.67% |
| Q1 2024 | 33.53% |
| Q4 2023 | -12.91% |
| Q3 2023 | 9.47% |
| Q2 2023 | -10.86% |
| Q1 2023 | 327.61% |
| Q4 2022 | -76.66% |
| Q3 2022 | -13.40% |
| Q2 2022 | 29.29% |
| Q1 2022 | 145.74% |
| Q4 2021 | -60.43% |
| Q3 2021 | 1.24% |
| Q2 2021 | 52.24% |
| Q1 2021 | -7.52% |
| Q4 2020 | 24.86% |
| Q3 2020 | 8.56% |
| Q2 2020 | 90.19% |
| Q1 2020 | -6.75% |
| Q4 2019 | -0.58% |
| Q3 2019 | 60.12% |
| Q2 2019 | 0.58% |
| Q1 2019 | 0.00% |